5alpha-Reductase Inhibitors Dampen L-DOPA-Induced Dyskinesia via Normalization of Dopamine D1-Receptor Signaling Pathway and D1-D3 Receptor Interaction

    September 2018 in “ Neurobiology of Disease ”
    Silvia Fanni, Simona Scheggi, Francesca Rossi, Elisabetta Tronci, Francesco Traccis, Roberto Stancampiano, Maria Graziella De Montis, Paola Devoto, Carla Gambarana, Marco Bortolato, Roberto Frau, Manolo Carta
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Image
    Studysummary This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses. Our plain-language summary of this paper — not a Tressless recommendation.
    In the 2019 study, finasteride (FIN) and dutasteride (DUTA), both 5alpha-reductase inhibitors, were found to significantly reduce L-DOPA-induced dyskinesia (LID) in a rat model of Parkinson's disease without affecting the therapeutic effects of L-DOPA. DUTA was more effective at lower doses and did not impact motor activation, suggesting it could be a better option for controlling dyskinesia without compromising the benefits of L-DOPA. The study, which included groups of 7-13 rats, showed that these inhibitors prevented the upregulation of striatal dopamine D1 receptor-related signaling pathways and reduced the interaction between D1 and D3 receptors, indicating a potential new therapeutic target for dyskinesia in Parkinson's disease.
    Discuss this study in the Community →

    Research cited in this study

    13 / 13 results